Candidate medical countermeasures targeting Ebola virus cell entry

Janie Liang, Rohit Jangra, Laura Bollinger, Jiro Wada, Sheli R. Radoshitzky, Kartik Chandran, Peter B. Jahrling, Jens H. Kuhn, Kenneth S. Jensen

Research output: Contribution to journalReview article

Abstract

Medical countermeasures (MCMs) against virus infections ideally prevent the adsorption or entry of virions into target cells, thereby circumventing infection. Recent significant advances in elucidating the mechanism of Ebola virus (EBOV) host-cell penetration include the involvement of two-pore channels at the early stage of entry, and identification of cellular proteases for EBOV spike glycoprotein maturation and the intracellular EBOV receptor, Niemann-Pick type C1. This improved understanding of the initial steps of EBOV infection is now increasingly applied to rapid development of candidate MCMs, some of which have already entered the clinic. Candidate MCMs discussed include antibodies, small molecules and peptides that target various stages of the described EBOV cell-entry pathway. In this review, we summarize the currently known spectrum of EBOV cell-entry inhibitors, describe their mechanism of action and evaluate their potential for future development.

Original languageEnglish (US)
Pages (from-to)119-140
Number of pages22
JournalFuture Virology
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Ebolavirus
Virus Internalization
Ebola Hemorrhagic Fever
Virus Receptors
Virus Diseases
Virion
Adsorption
Peptide Hydrolases
Peptides
Antibodies
Infection

Keywords

  • antibody therapeutics
  • antiviral
  • Ebola virus
  • ebolavirus
  • EBOV
  • entry inhibitor
  • Filoviridae
  • filovirus
  • glycoprotein
  • MCM
  • medical countermeasure
  • VHF
  • viral hemorrhagic fever
  • virus cell entry

ASJC Scopus subject areas

  • Virology

Cite this

Liang, J., Jangra, R., Bollinger, L., Wada, J., Radoshitzky, S. R., Chandran, K., ... Jensen, K. S. (2017). Candidate medical countermeasures targeting Ebola virus cell entry. Future Virology, 12(3), 119-140. https://doi.org/10.2217/fvl-2016-0113

Candidate medical countermeasures targeting Ebola virus cell entry. / Liang, Janie; Jangra, Rohit; Bollinger, Laura; Wada, Jiro; Radoshitzky, Sheli R.; Chandran, Kartik; Jahrling, Peter B.; Kuhn, Jens H.; Jensen, Kenneth S.

In: Future Virology, Vol. 12, No. 3, 01.03.2017, p. 119-140.

Research output: Contribution to journalReview article

Liang, J, Jangra, R, Bollinger, L, Wada, J, Radoshitzky, SR, Chandran, K, Jahrling, PB, Kuhn, JH & Jensen, KS 2017, 'Candidate medical countermeasures targeting Ebola virus cell entry', Future Virology, vol. 12, no. 3, pp. 119-140. https://doi.org/10.2217/fvl-2016-0113
Liang, Janie ; Jangra, Rohit ; Bollinger, Laura ; Wada, Jiro ; Radoshitzky, Sheli R. ; Chandran, Kartik ; Jahrling, Peter B. ; Kuhn, Jens H. ; Jensen, Kenneth S. / Candidate medical countermeasures targeting Ebola virus cell entry. In: Future Virology. 2017 ; Vol. 12, No. 3. pp. 119-140.
@article{02d519f8061145268b42c27ea9f8697c,
title = "Candidate medical countermeasures targeting Ebola virus cell entry",
abstract = "Medical countermeasures (MCMs) against virus infections ideally prevent the adsorption or entry of virions into target cells, thereby circumventing infection. Recent significant advances in elucidating the mechanism of Ebola virus (EBOV) host-cell penetration include the involvement of two-pore channels at the early stage of entry, and identification of cellular proteases for EBOV spike glycoprotein maturation and the intracellular EBOV receptor, Niemann-Pick type C1. This improved understanding of the initial steps of EBOV infection is now increasingly applied to rapid development of candidate MCMs, some of which have already entered the clinic. Candidate MCMs discussed include antibodies, small molecules and peptides that target various stages of the described EBOV cell-entry pathway. In this review, we summarize the currently known spectrum of EBOV cell-entry inhibitors, describe their mechanism of action and evaluate their potential for future development.",
keywords = "antibody therapeutics, antiviral, Ebola virus, ebolavirus, EBOV, entry inhibitor, Filoviridae, filovirus, glycoprotein, MCM, medical countermeasure, VHF, viral hemorrhagic fever, virus cell entry",
author = "Janie Liang and Rohit Jangra and Laura Bollinger and Jiro Wada and Radoshitzky, {Sheli R.} and Kartik Chandran and Jahrling, {Peter B.} and Kuhn, {Jens H.} and Jensen, {Kenneth S.}",
year = "2017",
month = "3",
day = "1",
doi = "10.2217/fvl-2016-0113",
language = "English (US)",
volume = "12",
pages = "119--140",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Candidate medical countermeasures targeting Ebola virus cell entry

AU - Liang, Janie

AU - Jangra, Rohit

AU - Bollinger, Laura

AU - Wada, Jiro

AU - Radoshitzky, Sheli R.

AU - Chandran, Kartik

AU - Jahrling, Peter B.

AU - Kuhn, Jens H.

AU - Jensen, Kenneth S.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Medical countermeasures (MCMs) against virus infections ideally prevent the adsorption or entry of virions into target cells, thereby circumventing infection. Recent significant advances in elucidating the mechanism of Ebola virus (EBOV) host-cell penetration include the involvement of two-pore channels at the early stage of entry, and identification of cellular proteases for EBOV spike glycoprotein maturation and the intracellular EBOV receptor, Niemann-Pick type C1. This improved understanding of the initial steps of EBOV infection is now increasingly applied to rapid development of candidate MCMs, some of which have already entered the clinic. Candidate MCMs discussed include antibodies, small molecules and peptides that target various stages of the described EBOV cell-entry pathway. In this review, we summarize the currently known spectrum of EBOV cell-entry inhibitors, describe their mechanism of action and evaluate their potential for future development.

AB - Medical countermeasures (MCMs) against virus infections ideally prevent the adsorption or entry of virions into target cells, thereby circumventing infection. Recent significant advances in elucidating the mechanism of Ebola virus (EBOV) host-cell penetration include the involvement of two-pore channels at the early stage of entry, and identification of cellular proteases for EBOV spike glycoprotein maturation and the intracellular EBOV receptor, Niemann-Pick type C1. This improved understanding of the initial steps of EBOV infection is now increasingly applied to rapid development of candidate MCMs, some of which have already entered the clinic. Candidate MCMs discussed include antibodies, small molecules and peptides that target various stages of the described EBOV cell-entry pathway. In this review, we summarize the currently known spectrum of EBOV cell-entry inhibitors, describe their mechanism of action and evaluate their potential for future development.

KW - antibody therapeutics

KW - antiviral

KW - Ebola virus

KW - ebolavirus

KW - EBOV

KW - entry inhibitor

KW - Filoviridae

KW - filovirus

KW - glycoprotein

KW - MCM

KW - medical countermeasure

KW - VHF

KW - viral hemorrhagic fever

KW - virus cell entry

UR - http://www.scopus.com/inward/record.url?scp=85014869955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014869955&partnerID=8YFLogxK

U2 - 10.2217/fvl-2016-0113

DO - 10.2217/fvl-2016-0113

M3 - Review article

AN - SCOPUS:85014869955

VL - 12

SP - 119

EP - 140

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 3

ER -